Supernus Pharmaceuticals (SUPN) Work In Process (2013 - 2026)

Supernus Pharmaceuticals (SUPN) has 14 years of Work In Process data on file, last reported at $36.1 million in Q1 2026.

• On a quarterly basis, Work In Process rose 92.85% year-over-year to $36.1 million in Q1 2026; TTM through Mar 2026 was $36.1 million, a 92.85% increase from a year earlier, with the FY2025 full-year figure at $29.4 million, up 10.14% from the prior year.
• Work In Process for Q1 2026 stood at $36.1 million, up from $29.4 million in the prior quarter.
• Over the last five years, Work In Process for SUPN reached as high as $46.2 million in Q1 2022 and fell as low as $15.6 million in Q2 2025.
• Historically, Work In Process has averaged $28.9 million across 5 years, with a median of $28.1 million in 2024.
• Across the five-year window, Work In Process surged 395.38% in 2022 and plunged 36.0% in 2023, its largest moves.
• Year by year, Work In Process stood at $31.7 million in 2022, then dropped by 1.57% to $31.2 million in 2023, then dropped by 14.38% to $26.7 million in 2024, then gained by 10.14% to $29.4 million in 2025, then advanced by 22.48% to $36.1 million in 2026.
• Per Business Quant data, the three most recent Work In Process figures were $36.1 million in Q1 2026, $29.4 million in Q4 2025, and $33.4 million in Q3 2025.